NEUROTROPE, INC. (OTCMKTS:NTRPD) Files An 8-K Other Events
Item 8.01.
| Other Events. |
On March 27, 2017, Neurotrope, Inc. (the Company) issued a press
release announcing that its common stock had been approved for
listing on the NASDAQ Capital Market, and that it expects to
commence trading under its current symbol NTRP on or about March
29, 2017. A copy of the press release is attached as Exhibit 99.1
to this report and is incorporated herein by reference.
| Item 9.01 | Financial Statements and Exhibits. |
(d) Exhibits.
| Exhibit Number | Description of Exhibits | |
| 99.1 | Press release of Neurotrope, Inc., dated March 27, 2017. |
About NEUROTROPE, INC. (OTCMKTS:NTRPD)
Neurotrope, Inc., formerly BlueFlash Communications, Inc., is a biopharmaceutical company with its product candidates in pre-clinical and clinical development. The Company is focused on developing a product platform based upon a drug candidate called bryostatin for the treatment of Alzheimer’s disease (AD), which is in the clinical testing stage. Bryostatin, which is a protein kinase C (PKC) Alpha and e activator, is also developed for other neurodegenerative or cognitive diseases and dysfunctions, which are in pre-clinical testing. Its second generation PKC activators, such as the Bryologs are meant for the treatment of central nervous system disorders, lysosomal storage diseases, stroke, cardio protection and traumatic brain injury. It develops Bryostatin-1 for the treatment of Alzheimer’s disease along with the rare (Orphan) diseases, such as Fragile X Syndrome and Niemann-Pick Type C. It has completed Phase IIa clinical trials of Bryostatin-1 for the treatment of patients with AD. NEUROTROPE, INC. (OTCMKTS:NTRPD) Recent Trading Information
NEUROTROPE, INC. (OTCMKTS:NTRPD) closed its last trading session 00.00 at 19.35 with 37,547 shares trading hands.